In naturally aged mice, FOXO4-DRI treatment reversed age-associated features including fur loss, renal dysfunction, and reduced fitness
Compare Tesamorelin by mechanism, evidence strength, expected timeline, side-effect profile, and whether its primary use case matches your goal
11.8% average weight loss as monotherapy in Phase 3 trialsclinically significant and comparable to first-generation GLP-1 medications
(2021) 41:BSR20211634
Dose range 100 to 300 mcg per shot
While these drugs show potential in reducing amyloid plaque burden, they come with risks such as amyloid-related imaging abnormalities with edema (ARIA-E), which can pose significant challenges to their widespread clinical use (Kurkinen, 2023